In contrast to PD-L1, multiple CD8 measures have more consistently demonstrated that CD8+ TIL densities are associated with longer survival in NSCLC patients who are not receiving ICT [32–35]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.